|Bid||11.17 x 900|
|Ask||13.44 x 4000|
|Day's Range||12.50 - 13.39|
|52 Week Range||8.27 - 16.27|
|Beta (3Y Monthly)||1.70|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 5, 2019 - Aug 9, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||18.64|
It hasn't been the best quarter for Amicus Therapeutics, Inc. (NASDAQ:FOLD) shareholders, since the share price has...
Supports Clinical and Commercial Supply Needs for Pompe and Other Lysosomal Disease Gene Therapy Programs Advances Amicus’ Mission to Deliver Novel Gene Therapies to Rare.
Amicus Therapeutics, Inc. (FOLD) has entered into a strategic manufacturing collaboration with Thermo Fisher Scientific1. Thermo Fisher, a best-in-class contract development and manufacturing organization (CDMO) with late-stage clinical and commercial-scale capabilities provides Amicus with immediate clinical and commercial manufacturing capabilities and capacity for the Amicus intrathecal AAV Batten disease gene therapy programs.
Before putting in our own effort and resources into finding a good investment, we can quickly utilize hedge fund expertise to give us a quick glimpse of whether that stock could make for a good addition to our portfolios. The odds are not exactly stacked in investors' favor when it comes to beating the market, […]
Amicus Therapeutics (FOLD) today announced two new additions to the Senior Leadership Team. Jill Weimer, PhD, a developmental neuroscientist and recognized thought leader in the field of neurologic rare disease gene therapy science, has joined as Senior Vice President of Discovery Research and Gene Therapy Science.
The company reportedly considered other cities for a new facility, but the Orlando City Council approved a nearly $380,000 incentive deal Aug. 20 to attract it to Central Florida.
As discussed in my column on Monday, small biotechs that need to raise money over the next 12 months as they ramp up sales on recently approved products have been particularly hit hard. Developmental concerns with no approved products are doing much better provided they have adequate cash runways. Data support what should be a successful New Drug Application (NDA) in the near future, but the information wasn't as overwhelming positive as some investors evidently hoped for as MacroGenics shares saw some profit taking in the days after the event.
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
CRANBURY, N.J., June 04, 2019 -- Amicus Therapeutics (Nasdaq: FOLD) today announced the closing of its previously announced offering of common stock. The Company issued a total.
CRANBURY, N.J., June 03, 2019 -- Amicus Therapeutics (Nasdaq: FOLD) today announced upcoming presentations at the following scientific and investor conferences in June..
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 30) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Misonix, ...
Amicus Therapeutics (FOLD) today announced the pricing of an underwritten offering of 16,279,070 shares of its common stock at $10.75 per share. The gross proceeds from the offering to Amicus are expected to be $175 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Amicus. In addition, Amicus has granted the underwriters a 30-day option to purchase up to an additional 2,441,860 shares of its common stock.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 29) Chiasma Inc (NASDAQ: CHMA ) Soliton Inc (NASDAQ: SOLY ...
Amicus Therapeutics (FOLD) today announced it has commenced a $150 million underwritten public offering of its common stock. J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and SVB Leerink LLC are acting as joint book-running managers for the proposed offering. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the final size or terms of the offering.
The expanded collaboration and licensing deal will include Amicus providing $50 million in research funding, over five years, to Penn's gene therapy program.
Exclusive Disease-Specific Worldwide Rights to Penn’s Next Generation Gene Therapy Technologies from the Wilson Lab for the Majority of Lysosomal Disorders Current.
Amicus or Portola: Which Is the Best Bet in May?(Continued from Prior Part)Vision for fiscal 2023In its investor presentation, Amicus Therapeutics (FOLD) has guided for revenues of around $200 million and $300 million for its AT-GAA Novel ERT
Amicus or Portola: Which Is the Best Bet in May?(Continued from Prior Part)Performance in the first quarterIn the first quarter, Amicus Therapeutics (FOLD) reported 150 net new patients using Galafold therapy, meaning the total number of patients
Amicus or Portola: Which Is the Best Bet in May?(Continued from Prior Part)First-quarter performanceIn the first quarter, Amicus Therapeutics (FOLD) reported non-GAAP EPS of -$0.39, a YoY fall of 39.29% and lower than the consensus estimate by
Amicus or Portola: Which Is the Best Bet in May?(Continued from Prior Part)Revenue guidanceIn its investor presentation, Amicus Therapeutics (FOLD) has guided for the revenues of its lead asset, Galafold, to fall in the range of $160 million to $180